CABOTIB 20MG TAB 30'S

About

Cabozantinib is a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, approved for the treatment of several advanced malignancies, including renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. This potent agent exerts its anti-cancer effects by simultaneously blocking the activity of multiple RTKs that are critically involved in tumor growth, angiogenesis, and metastasis. Key targets include MET, VEGFR1, 2, and 3, AXL, and RET. By inhibiting these diverse signaling pathways, cabozantinib effectively disrupts the processes that drive cancer progression, such as cell proliferation, survival, and the formation of new blood vessels that supply tumors. This comprehensive blockade helps to slow tumor growth, reduce tumor burden, and improve clinical outcomes for patients with these challenging cancers.

Uses

• Treatment of advanced renal cell carcinoma.
• Management of hepatocellular carcinoma.
• Treatment of differentiated thyroid cancer.
• Used in specific metastatic solid tumors.

Directions For Use

Take orally once daily on an empty stomach, at least 2 hours before or 1 hour after food.

Benefits

• Effective against multiple advanced cancers.
• Targets key pathways in tumor growth and spread.
• Can improve progression-free survival.
• Offers a treatment option for refractory cancers.
• Oral administration for convenience.
• Demonstrated efficacy in clinical trials.

Side Effects

• Diarrhea
• Fatigue
• Nausea
• Decreased appetite
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Hypertension (high blood pressure)
• Weight loss
• Vomiting
• Abdominal pain
• Stomatitis (mouth sores)
• Dysphonia (hoarseness)
• Proteinuria (protein in urine)

Safety Measures

• Alcohol - Avoid or limit alcohol as it may exacerbate gastrointestinal side effects or liver toxicity.
• Pregnancy - Contraindicated; can cause fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment and for a period after the last dose.
• Liver - Use with caution and potential dose reduction in patients with moderate to severe liver impairment.
• Kidney - Use with caution in patients with severe kidney impairment; monitor renal function closely.
• Lung - Monitor for potential pulmonary complications such as pneumonitis, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.